Verastem Oncology to Participate in Upcoming Investor Conferences
05 9월 2023 - 8:00PM
Business Wire
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company
committed to advancing new medicines for patients with cancer,
today announced that the Company will participate in the following
upcoming investor conferences:
- H.C. Wainwright 25th Annual Global Investment Conference;
podium presentation on Tuesday, September 12, 2023 at 2:00 p.m.
ET
- 2023 Cantor Global Healthcare Conference; fireside chat on
Tuesday, September 26, 2023 at 9:55 a.m. ET
A live webcast of the presentation and fireside chat will be
available on the investors section of the Company’s website at
www.verastem.com. An archived replay of the presentation and
fireside chat will be made available on the same website for
approximately 90 days following each event.
About Verastem Oncology Verastem Oncology (Nasdaq: VSTM) is a
development-stage biopharmaceutical company committed to the
development and commercialization of new medicines to improve the
lives of patients diagnosed with cancer. Our pipeline is focused on
novel small molecule drugs that inhibit critical signaling pathways
in cancer that promote cancer cell survival and tumor growth,
including RAF/MEK inhibition and focal adhesion kinase (FAK)
inhibition. For more information, please visit
www.verastem.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230905929024/en/
Investors: Dan Calkins Investor Relations +1 781-469-1694
dcalkins@verastem.com
Ryan Porter +1 212-600-1902 ryan.porter@argotpartners.com
Media: Lisa Buffington Corporate Communications +1 (781)
292-4502 lbuffington@verastem.com
Verastem (NASDAQ:VSTM)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Verastem (NASDAQ:VSTM)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
